Document Detail


Recombinant peptides in thrombolysis.
MedLine Citation:
PMID:  20632250     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are alteplase (t-PA), reteplase (r-PA), and tenecteplase (TNK). r-PA and TNK have been structurally modified from native t-PA to increase their half-life and fibrin specificity. Thrombolytics play an important role in several diseases, including ST-segment elevation myocardial infarction (STEMI), deep vein thrombosis (DVT) and pulmonary embolism (PE), ischemic stroke, and peripheral arterial disease. Thrombolytic therapy has evolved into an alternative treatment for STEMI, reserved predominantly for patients who do not have access to timely percutaneous coronary intervention. In patients with DVT/PE or arterial related critical limb ischemia, the use of thrombolytic therapy is limited to specific patient populations. Thrombolytic therapy is the treatment of choice for ischemic stroke in patients who present <or=3 hours following the onset of symptoms. Moreover, thrombolytic therapy is used to restore function to stenotized central venous access devices as well as occluded hemodialysis access grafts.
Authors:
Jennifer Campbell; Daniel Hilleman
Publication Detail:
Type:  Journal Article; Review     Date:  2010-07-14
Journal Detail:
Title:  Seminars in thrombosis and hemostasis     Volume:  36     ISSN:  1098-9064     ISO Abbreviation:  Semin. Thromb. Hemost.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-15     Completed Date:  2010-10-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0431155     Medline TA:  Semin Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  529-36     Citation Subset:  IM    
Affiliation:
Creighton Cardiac Center, Omaha, Nebraska 68178, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fibrinolytic Agents / therapeutic use
Humans
Recombinant Proteins / therapeutic use*
Thrombolytic Therapy / methods*
Tissue Plasminogen Activator / therapeutic use*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Recombinant Proteins; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preclinical Testing of Human Recombinant von Willebrand Factor: ADAMTS13 Cleavage Capacity in Animal...
Next Document:  Thrombotic Complications of Erythropoiesis-Stimulating Agents.